Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.
复制标题
DOI:
10.1021/jm100884b
复制
发表时间:
2010-10-28
影响因子:
7.3
通讯作者:
Li W
中科院分区:
文献类型:
--
作者:
Chen J;Wang Z;Li CM;Lu Y;Vaddady PK;Meibohm B;Dalton JT;Miller DD;Li W
A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4-carboxylic amide (AICA) derivatives and 4-substituted methoxylbenzoyl-aryl-thiazoles (SMART). The average IC50 of the most active compound (5da) was 15.7 nM. ABI analogs have substantially improved aqueous solubility (48.9 μg/mL for 5ga vs. 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for Combretastatin A4). Mechanism of action studies indicate that the anticancer activity of ABI analogs is through inhibition of tubulin polymerization by interacting with the colchicine binding site. Unlike paclitaxel and colchicine, the ABI compounds were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells. In vivo results indicated that 5cb was more effective than DTIC in inhibiting melanoma xenograph tumor growth. Our results suggest that the novel ABI compounds may be developed to effectively treat drug-resistant tumors.
登录
查看更多内容
影响因子:
7.3
作者:
Lu Y;Li CM;Wang Z;Ross CR 2nd;Chen J;Dalton JT;Li W;Miller DD
通讯作者:
Miller DD
影响因子:
8.8
作者:
Leonessa, F;Green, D;Licht, T;Wright, A;WingateLegette, K;Lippman, J;Gottesman, MM;Clarke, R
通讯作者:
Clarke, R
影响因子:
2.7
作者:
Chen, Jianjun;Wang, Zhao;Li, Wei
通讯作者:
Li, Wei
影响因子:
3.8
作者:
Glomme, A;März, J;Dressman, JB
通讯作者:
Dressman, JB
影响因子:
2.7
作者:
Bellina, Fabio;Cauteruccio, Silvia;Rossi, Renzo
通讯作者:
Rossi, Renzo